Clinical Trials Logo

Pancreatic Carcinoma Metastatic clinical trials

View clinical trials related to Pancreatic Carcinoma Metastatic.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04659603 Active, not recruiting - Clinical trials for Breast Cancer Metastatic

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

CARMEN-BT01
Start date: March 29, 2021
Phase: Phase 2
Study type: Interventional

Primary Objective: - For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with gemcitabine in metastatic pancreatic adenocarcinoma (mPAC) - For Cohort C Part 1: Confirmation of the recommended tusamitamab ravtansine dose when administered in combination with gemcitabine Secondary Objectives: - To assess the safety and tolerability of tusamitamab ravtansine administered as monotherapy and in combination with gemcitabine - To assess other efficacy parameters of tusamitamab ravtansine administered as monotherapy and in combination with gemcitabine - To assess the immunogenicity of tusamitamab ravtansine - To assess the pharmacokinetics (PK) of tusamitamab ravtansine and gemcitabine when given in combination